Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose

Phase 3

50%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Jun 16

BNTX⭐Phase 3Phase 3

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose Phase 3 Results Expected

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose • SARS-CoV-2 Virus

Drug Information

Target Indication

SARS-CoV-2 Virus

Clinical Trial

Last updated: 12/4/2025